Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001628280-24-014888
Filing Date
2024-04-04
Accepted
2024-04-04 16:42:05
Documents
16
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ngm-20231231.htm   iXBRL 10-K/A 491700
2 EX-31.3 ngm-20231231x10kaex313.htm EX-31.3 5069
3 EX-31.4 ngm-20231231x10kaex314.htm EX-31.4 5100
  Complete submission text file 0001628280-24-014888.txt   760320

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20231231.xsd EX-101.SCH 2515
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20231231_lab.xml EX-101.LAB 35958
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20231231_pre.xml EX-101.PRE 20924
19 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20231231_htm.xml XML 4901
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38853 | Film No.: 24823645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)